Approval Date: Apr 2021
For the management of neuropathic pain associated with diabetic neuropathy; post-herpetic neuralgia. While previous generic versions of Lyrica have been approved in the past, this generic approval is for the Extended-Release tablets
Approval Date: Mar 2021
For the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Approval Date: Mar 2021
For the treatment of severe hypoglycemia in diabetic patients
Approval Date: Feb 2021
Indicated for 72-hour post-surgical analgesia following shoulder surgery
Approval Date: Feb 2021
A new 500 mg dose indicated for the management of mild to moderate pain, or moderate to severe pain with adjudicative opioid analgesics
Approval Date: Jan 2021
A complete regimen for the treatment of HIV-1 infection to replace current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure. This is the first FDA-approved injectable, complete regimen for HIV, administered once a month
Approval Date: Dec 2020
Indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection
Approval Date: Oct 2020
Indicated for the treatment of COVID-19 cases requiring hospitalization. Veklury should only be administered in a hospital or healthcare setting capable of providing acute care comparable to inpatient hospital care
Approval Date: Sep 2020
A new oral solution formulation, this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis
